Get the latest cancer news and research. Sort by cancer type or read the current headlines to learn what’s happening in the science of cancer detection and treatment, as well as healthy living tips for dealing with cancer.
29
The drug vorinostat is able to cross the blood- brain barrier and reduce the development of large metastatic tumors in mice brains by 62 percent when compared to mice that did not receive the drug, according to a new study.
Smokers who learn their personal risk of lung cancer through gene-based risk assessment are more likely to be motivated to quit their habit, according to Dr. W. Jeffrey Allard, clinical affairs director of Synergenz Bioscience Ltd.
27
U of T researchers have used nanomaterials to develop a microchip sensitive enough to quickly determine the type and severity of a patient's cancer so that the disease can be detected earlier for more effective treatment.
26
The doctors told Susan Smedley Gerber that her lung cancer wasn't caused by smoking but in many ways it didn't matter. She found herself facing the same stigma and same reactions that thousands of lung cancer patients fight in addition to their cancer.
25
Higher levels of environmental chemicals in breast milk are linked to a higher incidence of testicular cancer, researchers in Denmark found.
24
BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase III clinical trial evaluating its lead product, OncoVEX (GM-CSF), for the first-line treatment of patients with squamous cell cancer of the head and neck.
23
Regular, moderate UV exposure contributes to protection against breast, prostrate and colorectal cancer (colon and rectal cancer) as well as non Hodgkin's lymphoma (one of two forms of lymph node cancers).
22
U.S. researchers say they've discovered cancer predisposition resulting from the presence of a specific gene variant shows a strong gender bias.
A new technique for reconstructing the palate after surgery for tonsil cancer maintained patients' ability to speak clearly and eat most foods, a new study shows.
Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi- kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).
We care about your feedback. Let us know how we can improve your CancerCompass experience.